drugset / Trial / NCT05369286
A Study to Evaluate the Safety and Efficacy of Max-40279 and Toripalimab in Patients With Advanced Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This include two parts, part 1 is a dose escalation study and part 2 is a dose expansion study.
Timeline
- Start
- 2022-04-11
- Primary completion
- 2023-05-31
- Completion
- 2023-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MAX-40279-01 | Unknown | — | — |
| Subject | Toripalimab | Monoclonal antibody | — | — |